Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01156571 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
A Phase 3 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 11,145
- Enrollment target
NCT01156571 is a Phase 3 study that has completed, run by The Medicines Company. The registered enrollment target is 11,145 participants.
The verdict
NCT01156571, a Phase 3 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 11,145 participants
- Enrollment target
Study Summary
The study is designed to compare the efficacy and safety profile of cangrelor to standard of care in patients require percutaneous coronary intervention (PCI).
Interventions
- DRUG cangrelor P2Y12 (platelet) inhibitor
- DRUG Clopidogrel - 300 or 600 mg (study arm)
- DRUG Clopidogrel 600 mg post cangrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,145 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01156571
The ClinicalTrials.gov registry entry for NCT01156571 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 11,145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cangrelor P2Y12 (platelet) inhibitor is the first listed.
NCT01156571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01156571 about?
NCT01156571 is a clinical study titled "A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)". The study is designed to compare the efficacy and safety profile of cangrelor to standard of care in patients require percutaneous coronary intervention (PCI).
What is the current status of trial NCT01156571?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 11,145 participants. The study started on 2010-09. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01156571?
The interventions under investigation include: cangrelor P2Y12 (platelet) inhibitor (DRUG), Clopidogrel - 300 or 600 mg (study arm) (DRUG), Clopidogrel 600 mg post cangrelor (DRUG).
Who is sponsoring clinical trial NCT01156571?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.